Toshimasa Shimizu

Nagasaki, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 152 publications

Efficacy and safety of filgotinib versus tocilizumab in active rheumatoid arthritis: A randomized, open-label, multicenter study with clinical and musculoskeletal ultrasound evaluation (TRANSFORM study).

Efficacy and safety of filgotinib versus tocilizumab in active rheumatoid arthritis: A randomized, open-label, multicenter study with clinical and musculoskeletal ultrasound evaluation (TRANSFORM study).

Journal: Drug discoveries & therapeutics

Published: April 26, 2026

Early longitudinal proteomic changes during sirolimus therapy in tocilizumab-refractory idiopathic multicentric Castleman disease.

Early longitudinal proteomic changes during sirolimus therapy in tocilizumab-refractory idiopathic multicentric Castleman disease.

Journal: Rheumatology (Oxford, England)

Published: March 30, 2026

The relationship between obesity and disease relapse in systemic lupus erythematosus: a retrospective cohort study using the LUNA registry.

The relationship between obesity and disease relapse in systemic lupus erythematosus: a retrospective cohort study using the LUNA registry.

Journal: Frontiers in immunology

Published: January 06, 2026

Pre-treatment serum albumin predicts relapse in idiopathic inflammatory myopathies: a retrospective cohort study with cytokine profiling.

Pre-treatment serum albumin predicts relapse in idiopathic inflammatory myopathies: a retrospective cohort study with cytokine profiling.

Journal: Rheumatology advances in practice

Published: December 23, 2025

Polychondritis and Arthritis in a Patient with Coexisting Alkaptonuria and Psoriasis Vulgaris.

Polychondritis and Arthritis in a Patient with Coexisting Alkaptonuria and Psoriasis Vulgaris.

Journal: Internal medicine (Tokyo, Japan)

Published: December 10, 2025

A Placebo-Controlled Exploratory Trial of Sirolimus for Tocilizumab-Resistant Idiopathic Multicentric Castleman Disease: Early Termination and Long-Term Extension Results Based on Descriptive Results From Two Patients.

A Placebo-Controlled Exploratory Trial of Sirolimus for Tocilizumab-Resistant Idiopathic Multicentric Castleman Disease: Early Termination and Long-Term Extension Results Based on Descriptive Results From Two Patients.

Journal: Cureus

Published: December 01, 2025

Peripheral blood UBA1 variant burden predicts poor outcomes in VEXAS syndrome: a nationwide prospective study.

Peripheral blood UBA1 variant burden predicts poor outcomes in VEXAS syndrome: a nationwide prospective study.

Journal: Annals of the rheumatic diseases

Published: October 27, 2025

Efficacy and safety of efgartigimod PH20 SC for Sjögren's disease-associated dryness: study protocol for an investigator-initiated, multicenter, phase 2, randomized, double-blind, placebo-controlled trial (OASIS study).

Efficacy and safety of efgartigimod PH20 SC for Sjögren's disease-associated dryness: study protocol for an investigator-initiated, multicenter, phase 2, randomized, double-blind, placebo-controlled trial (OASIS study).

Journal: Frontiers in medicine

Published: October 06, 2025

Pretreatment Cytokine Signatures as Candidate Biomarkers for JAK Inhibitor Response in Anti-MDA5 Dermatomyositis-Related Interstitial Lung Disease: A Pilot Study.

Pretreatment Cytokine Signatures as Candidate Biomarkers for JAK Inhibitor Response in Anti-MDA5 Dermatomyositis-Related Interstitial Lung Disease: A Pilot Study.

Journal: ACR open rheumatology

Published: September 28, 2025

Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): An interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments.

Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): An interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments.

Journal: Drug discoveries & therapeutics

Published: August 24, 2025

Structural and Functional Outcomes in Rheumatoid Arthritis After 10-Year Therapy with Disease-Modifying Antirheumatic Drugs Under Tight Control: Evidence from Real-World Cohort Data.

Structural and Functional Outcomes in Rheumatoid Arthritis After 10-Year Therapy with Disease-Modifying Antirheumatic Drugs Under Tight Control: Evidence from Real-World Cohort Data.

Journal: Journal of clinical medicine

Published: August 22, 2025

Detection of Irpex lacteus in the Lung in a Case with Microscopic Polyangiitis-mimicking Manifestations Positive for Myeloperoxidase-antineutrophil Cytoplasmic Antibody.

Detection of Irpex lacteus in the Lung in a Case with Microscopic Polyangiitis-mimicking Manifestations Positive for Myeloperoxidase-antineutrophil Cytoplasmic Antibody.

Journal: Internal medicine (Tokyo, Japan)

Published: August 13, 2025

Showing 1-12 of 152

Last Updated: 09/26/2026